Surgery
SPARC Investigational Drug Shows Promise In Phase 3 Trial For Treating Inflammation, Pain Related To Ocular Surgery
SPARC Phase 3 Trial Results
SPARC Phase 3 Trial Results
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. SPARC said its investigational drug met pre-specified primary and secondary endpoints.
"SPARC reported positive top-line results from its phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. The trial met its pre-specified primary and secondary objectives," the company said in a regulatory filing.
Read also: SPARC, Sun Pharma enter into license agreement for SCD-044, a potential treatment for atopic dermatitis, psoriasis, more
The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.
Shares of SPARC were trading 0.56 per cent higher at Rs 170.30 apiece on BSE.
Read also: SPARC, Tripoint ink licensing pact for Elepsia XR tablets in US
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!